GRFS:NGS-Grifols S.A.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 21.39

Change

+0.31 (+1.47)%

Market Cap

USD 14.63B

Volume

0.39M

Yahoo Analyst Target

USD 23.30 (8.93%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Grifols SA is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. It operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

+1.90 (+0.94%)

USD 132.81B
GILD Gilead Sciences Inc.

+0.95 (+1.29%)

USD 97.01B
BIIB Biogen Inc.

+2.33 (+0.69%)

USD 68.74B
CELG Celgene Corporation

+0.92 (+1.05%)

USD 62.11B
SHPG Shire plc

+1.40 (+0.78%)

USD 47.05B
VRTX Vertex Pharmaceuticals Incorpo..

+3.92 (+2.22%)

USD 46.13B
REGN Regeneron Pharmaceuticals Inc.

+3.55 (+0.93%)

USD 41.84B
ALXN Alexion Pharmaceuticals Inc.

+2.64 (+2.16%)

USD 27.77B
BMRN BioMarin Pharmaceutical Inc.

+0.63 (+0.63%)

USD 17.83B
INCY Incyte Corporation

+1.03 (+1.53%)

USD 14.51B

ETFs Containing GRFS

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.68% 50% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.68% 49% F 32% F
Trailing 12 Months  
Capital Gain 2.89% 55% F 44% F
Dividend Return 0.78% 29% F 13% F
Total Return 3.66% 56% F 43% F
Trailing 5 Years  
Capital Gain 33.48% 64% D 49% F
Dividend Return 5.82% 29% F 22% F
Total Return 39.30% 65% D 47% F
Average Annual (5 Year Horizon)  
Capital Gain 5.82% 49% F 47% F
Dividend Return 7.10% 50% F 45% F
Total Return 1.28% 29% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 20.47% 89% B+ 62% D-
Risk Adjusted Return 34.67% 66% D 46% F
Market Capitalization 10.54B 98% A+ 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.10 2% F 10% F
Price/Book Ratio 7.64 26% F 16% F
Price / Cash Flow Ratio 8.99 3% F 10% F
Price/Free Cash Flow Ratio 62.91 2% F 7% F
Management Effectiveness  
Return on Equity 15.87% 86% B 80% B-
Return on Invested Capital 14.02% 88% B+ 78% C+
Return on Assets 5.66% 93% A 80% B-
Debt to Equity Ratio 103.75% 13% F 24% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

GRFS:NGS-Grifols S.A.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 21.39

Change

+0.31 (+1.47)%

Market Cap

USD 14.63B

Volume

0.39M

Yahoo Analyst Target

USD 23.30 (8.93%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-09-20